nodes	percent_of_prediction	percent_of_DWPC	metapath
Thalidomide—NFKB1—forebrain—attention deficit hyperactivity disorder	0.0535	0.0774	CbGeAlD
Thalidomide—NFKB1—cardiovascular system—attention deficit hyperactivity disorder	0.0453	0.0654	CbGeAlD
Thalidomide—CRBN—forebrain—attention deficit hyperactivity disorder	0.0449	0.0648	CbGeAlD
Thalidomide—FGFR2—forebrain—attention deficit hyperactivity disorder	0.0402	0.0581	CbGeAlD
Thalidomide—FGFR2—cardiovascular system—attention deficit hyperactivity disorder	0.034	0.0491	CbGeAlD
Thalidomide—CRBN—midbrain—attention deficit hyperactivity disorder	0.0296	0.0428	CbGeAlD
Thalidomide—NFKB1—nervous system—attention deficit hyperactivity disorder	0.0291	0.042	CbGeAlD
Thalidomide—NFKB1—central nervous system—attention deficit hyperactivity disorder	0.028	0.0404	CbGeAlD
Thalidomide—NFKB1—cerebellum—attention deficit hyperactivity disorder	0.0273	0.0395	CbGeAlD
Thalidomide—CRBN—nervous system—attention deficit hyperactivity disorder	0.0244	0.0352	CbGeAlD
Thalidomide—CRBN—central nervous system—attention deficit hyperactivity disorder	0.0235	0.0339	CbGeAlD
Thalidomide—CRBN—cerebellum—attention deficit hyperactivity disorder	0.0229	0.0331	CbGeAlD
Thalidomide—NFKB1—brain—attention deficit hyperactivity disorder	0.0222	0.0321	CbGeAlD
Thalidomide—FGFR2—nervous system—attention deficit hyperactivity disorder	0.0218	0.0315	CbGeAlD
Thalidomide—FGFR2—central nervous system—attention deficit hyperactivity disorder	0.021	0.0304	CbGeAlD
Thalidomide—FGFR2—cerebellum—attention deficit hyperactivity disorder	0.0205	0.0297	CbGeAlD
Thalidomide—CRBN—brain—attention deficit hyperactivity disorder	0.0186	0.0269	CbGeAlD
Thalidomide—FGFR2—brain—attention deficit hyperactivity disorder	0.0167	0.0241	CbGeAlD
Thalidomide—TNF—Matrix Metalloproteinases—MMP16—attention deficit hyperactivity disorder	0.0153	0.0496	CbGpPWpGaD
Thalidomide—PTGS1—forebrain—attention deficit hyperactivity disorder	0.0128	0.0185	CbGeAlD
Thalidomide—PTGS2—forebrain—attention deficit hyperactivity disorder	0.0122	0.0177	CbGeAlD
Thalidomide—NFKB1—Cytosolic sensors of pathogen-associated DNA—MB21D1—attention deficit hyperactivity disorder	0.012	0.0389	CbGpPWpGaD
Thalidomide—CYP2C9—cardiovascular system—attention deficit hyperactivity disorder	0.0118	0.0171	CbGeAlD
Thalidomide—CYP2E1—cardiovascular system—attention deficit hyperactivity disorder	0.0112	0.0162	CbGeAlD
Thalidomide—PTGS1—cardiovascular system—attention deficit hyperactivity disorder	0.0108	0.0156	CbGeAlD
Thalidomide—PTGS2—cardiovascular system—attention deficit hyperactivity disorder	0.0103	0.0149	CbGeAlD
Thalidomide—TNF—Monoamine Transport—TPH2—attention deficit hyperactivity disorder	0.00934	0.0303	CbGpPWpGaD
Thalidomide—TNF—Monoamine Transport—HRH3—attention deficit hyperactivity disorder	0.00919	0.0299	CbGpPWpGaD
Thalidomide—NFKB1—Cytosolic sensors of pathogen-associated DNA—POLR3A—attention deficit hyperactivity disorder	0.00878	0.0285	CbGpPWpGaD
Thalidomide—PTGS2—midbrain—attention deficit hyperactivity disorder	0.00807	0.0117	CbGeAlD
Thalidomide—NFKB1—p75 NTR receptor-mediated signalling—RTN4—attention deficit hyperactivity disorder	0.00804	0.0261	CbGpPWpGaD
Thalidomide—NFKB1—Melatonin metabolism and effects—MAOA—attention deficit hyperactivity disorder	0.00798	0.0259	CbGpPWpGaD
Thalidomide—CYP1A1—nervous system—attention deficit hyperactivity disorder	0.0079	0.0114	CbGeAlD
Thalidomide—NFKB1—Oxidative Stress—MAOA—attention deficit hyperactivity disorder	0.00777	0.0252	CbGpPWpGaD
Thalidomide—CYP1A1—central nervous system—attention deficit hyperactivity disorder	0.00761	0.011	CbGeAlD
Thalidomide—TNF—Monoamine Transport—SLC6A4—attention deficit hyperactivity disorder	0.00747	0.0243	CbGpPWpGaD
Thalidomide—CYP2E1—nervous system—attention deficit hyperactivity disorder	0.0072	0.0104	CbGeAlD
Thalidomide—PTGS1—nervous system—attention deficit hyperactivity disorder	0.00694	0.01	CbGeAlD
Thalidomide—CYP2E1—central nervous system—attention deficit hyperactivity disorder	0.00694	0.01	CbGeAlD
Thalidomide—CYP2E1—cerebellum—attention deficit hyperactivity disorder	0.00678	0.0098	CbGeAlD
Thalidomide—PTGS1—central nervous system—attention deficit hyperactivity disorder	0.00668	0.00965	CbGeAlD
Thalidomide—TNF—Monoamine Transport—SLC6A3—attention deficit hyperactivity disorder	0.00666	0.0216	CbGpPWpGaD
Thalidomide—PTGS2—nervous system—attention deficit hyperactivity disorder	0.00663	0.00958	CbGeAlD
Thalidomide—PTGS2—central nervous system—attention deficit hyperactivity disorder	0.00639	0.00923	CbGeAlD
Thalidomide—PTGS2—cerebellum—attention deficit hyperactivity disorder	0.00624	0.00902	CbGeAlD
Thalidomide—CYP1A1—brain—attention deficit hyperactivity disorder	0.00604	0.00872	CbGeAlD
Thalidomide—CYP2E1—brain—attention deficit hyperactivity disorder	0.00551	0.00796	CbGeAlD
Thalidomide—FGFR2—Signaling by ERBB2—STUB1—attention deficit hyperactivity disorder	0.00533	0.0173	CbGpPWpGaD
Thalidomide—PTGS1—brain—attention deficit hyperactivity disorder	0.0053	0.00766	CbGeAlD
Thalidomide—PTGS2—brain—attention deficit hyperactivity disorder	0.00507	0.00733	CbGeAlD
Thalidomide—CYP1A2—Methylation—COMT—attention deficit hyperactivity disorder	0.00502	0.0163	CbGpPWpGaD
Thalidomide—CYP1A1—Estrogen metabolism—COMT—attention deficit hyperactivity disorder	0.00492	0.016	CbGpPWpGaD
Thalidomide—TNF—Spinal Cord Injury—RTN4—attention deficit hyperactivity disorder	0.00458	0.0149	CbGpPWpGaD
Thalidomide—TNF—Alzheimers Disease—CACNA1C—attention deficit hyperactivity disorder	0.00415	0.0135	CbGpPWpGaD
Thalidomide—NFKB1—SIDS Susceptibility Pathways—TPH2—attention deficit hyperactivity disorder	0.00345	0.0112	CbGpPWpGaD
Thalidomide—CYP1A1—Melatonin metabolism and effects—MAOA—attention deficit hyperactivity disorder	0.00334	0.0108	CbGpPWpGaD
Thalidomide—CYP1A1—Oxidative Stress—MAOA—attention deficit hyperactivity disorder	0.00325	0.0106	CbGpPWpGaD
Thalidomide—NFKB1—Initiation of transcription and translation elongation at the HIV-1 LTR—EP300—attention deficit hyperactivity disorder	0.00319	0.0103	CbGpPWpGaD
Thalidomide—CYP1A2—Estrogen metabolism—COMT—attention deficit hyperactivity disorder	0.00314	0.0102	CbGpPWpGaD
Thalidomide—NFKB1—SIDS Susceptibility Pathways—CHRNA4—attention deficit hyperactivity disorder	0.00297	0.00964	CbGpPWpGaD
Thalidomide—NFKB1—Signaling by NGF—RTN4—attention deficit hyperactivity disorder	0.00296	0.00961	CbGpPWpGaD
Thalidomide—PTGS2—Spinal Cord Injury—RTN4—attention deficit hyperactivity disorder	0.00283	0.0092	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by NGF—RTN4—attention deficit hyperactivity disorder	0.00281	0.00912	CbGpPWpGaD
Thalidomide—NFKB1—SIDS Susceptibility Pathways—SLC6A4—attention deficit hyperactivity disorder	0.00276	0.00897	CbGpPWpGaD
Thalidomide—NFKB1—SIDS Susceptibility Pathways—SNAP25—attention deficit hyperactivity disorder	0.00276	0.00897	CbGpPWpGaD
Thalidomide—CYP2C19—Melatonin metabolism and effects—MAOA—attention deficit hyperactivity disorder	0.00273	0.00887	CbGpPWpGaD
Thalidomide—TNF—SIDS Susceptibility Pathways—TPH2—attention deficit hyperactivity disorder	0.00263	0.00854	CbGpPWpGaD
Thalidomide—NFKB1—Aryl Hydrocarbon Receptor—EP300—attention deficit hyperactivity disorder	0.00238	0.00774	CbGpPWpGaD
Thalidomide—TNF—SIDS Susceptibility Pathways—CHRNA4—attention deficit hyperactivity disorder	0.00226	0.00735	CbGpPWpGaD
Thalidomide—PTGS1—Phase 1 - Functionalization of compounds—MAOA—attention deficit hyperactivity disorder	0.00215	0.00697	CbGpPWpGaD
Thalidomide—NFKB1—BDNF signaling pathway—BDNF—attention deficit hyperactivity disorder	0.00214	0.00694	CbGpPWpGaD
Thalidomide—CYP1A2—Melatonin metabolism and effects—MAOA—attention deficit hyperactivity disorder	0.00213	0.00691	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—MB21D1—attention deficit hyperactivity disorder	0.00211	0.00686	CbGpPWpGaD
Thalidomide—TNF—SIDS Susceptibility Pathways—SNAP25—attention deficit hyperactivity disorder	0.0021	0.00683	CbGpPWpGaD
Thalidomide—TNF—SIDS Susceptibility Pathways—SLC6A4—attention deficit hyperactivity disorder	0.0021	0.00683	CbGpPWpGaD
Thalidomide—NFKB1—IL-4 Signaling Pathway—EP300—attention deficit hyperactivity disorder	0.0021	0.00681	CbGpPWpGaD
Thalidomide—NFKB1—TGF-beta Receptor Signaling—EP300—attention deficit hyperactivity disorder	0.0021	0.00681	CbGpPWpGaD
Thalidomide—NFKB1—SIDS Susceptibility Pathways—MAOA—attention deficit hyperactivity disorder	0.00208	0.00675	CbGpPWpGaD
Thalidomide—NFKB1—SIDS Susceptibility Pathways—BDNF—attention deficit hyperactivity disorder	0.002	0.00651	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—MB21D1—attention deficit hyperactivity disorder	0.002	0.00651	CbGpPWpGaD
Thalidomide—NFKB1—Adaptive Immune System—STUB1—attention deficit hyperactivity disorder	0.00196	0.00638	CbGpPWpGaD
Thalidomide—NFKB1—Developmental Biology—ANK3—attention deficit hyperactivity disorder	0.00195	0.00633	CbGpPWpGaD
Thalidomide—TNF—Spinal Cord Injury—BDNF—attention deficit hyperactivity disorder	0.00191	0.0062	CbGpPWpGaD
Thalidomide—NFKB1—Notch Signaling Pathway—EP300—attention deficit hyperactivity disorder	0.0019	0.00618	CbGpPWpGaD
Thalidomide—NFKB1—MAPK Signaling Pathway—BDNF—attention deficit hyperactivity disorder	0.00189	0.00613	CbGpPWpGaD
Thalidomide—FGFR2—Adaptive Immune System—STUB1—attention deficit hyperactivity disorder	0.00186	0.00605	CbGpPWpGaD
Thalidomide—TNF—Aryl Hydrocarbon Receptor Pathway—EP300—attention deficit hyperactivity disorder	0.00182	0.0059	CbGpPWpGaD
Thalidomide—TNF—Aryl Hydrocarbon Receptor—EP300—attention deficit hyperactivity disorder	0.00182	0.0059	CbGpPWpGaD
Thalidomide—NFKB1—Cytosolic sensors of pathogen-associated DNA—EP300—attention deficit hyperactivity disorder	0.00179	0.0058	CbGpPWpGaD
Thalidomide—NFKB1—Integrated Pancreatic Cancer Pathway—BDNF—attention deficit hyperactivity disorder	0.0017	0.00554	CbGpPWpGaD
Thalidomide—NFKB1—Signaling events mediated by HDAC Class I—EP300—attention deficit hyperactivity disorder	0.0017	0.00553	CbGpPWpGaD
Thalidomide—NFKB1—SIDS Susceptibility Pathways—HTR2A—attention deficit hyperactivity disorder	0.00169	0.0055	CbGpPWpGaD
Thalidomide—CYP2E1—Phase 1 - Functionalization of compounds—MAOA—attention deficit hyperactivity disorder	0.0016	0.00521	CbGpPWpGaD
Thalidomide—CYP3A5—Phase 1 - Functionalization of compounds—MAOA—attention deficit hyperactivity disorder	0.0016	0.0052	CbGpPWpGaD
Thalidomide—TNF—TGF-beta Receptor Signaling—EP300—attention deficit hyperactivity disorder	0.0016	0.00519	CbGpPWpGaD
Thalidomide—TNF—SIDS Susceptibility Pathways—MAOA—attention deficit hyperactivity disorder	0.00158	0.00514	CbGpPWpGaD
Thalidomide—NFKB1—Transcriptional regulation of white adipocyte differentiation—EP300—attention deficit hyperactivity disorder	0.00158	0.00513	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—POLR3A—attention deficit hyperactivity disorder	0.00155	0.00503	CbGpPWpGaD
Thalidomide—NFKB1—RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways—EP300—attention deficit hyperactivity disorder	0.00153	0.00497	CbGpPWpGaD
Thalidomide—TNF—SIDS Susceptibility Pathways—BDNF—attention deficit hyperactivity disorder	0.00153	0.00496	CbGpPWpGaD
Thalidomide—CYP1A1—Phase 1 - Functionalization of compounds—MAOA—attention deficit hyperactivity disorder	0.00151	0.00491	CbGpPWpGaD
Thalidomide—NFKB1—Glucocorticoid receptor regulatory network—EP300—attention deficit hyperactivity disorder	0.0015	0.00487	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—ANK3—attention deficit hyperactivity disorder	0.00149	0.00482	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—POLR3A—attention deficit hyperactivity disorder	0.00147	0.00478	CbGpPWpGaD
Thalidomide—TNF—MAPK Signaling Pathway—BDNF—attention deficit hyperactivity disorder	0.00144	0.00467	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways in Glioblastoma—EP300—attention deficit hyperactivity disorder	0.00142	0.00462	CbGpPWpGaD
Thalidomide—NFKB1—Developmental Biology—CACNB2—attention deficit hyperactivity disorder	0.00137	0.00446	CbGpPWpGaD
Thalidomide—TNF—Integrated Pancreatic Cancer Pathway—BDNF—attention deficit hyperactivity disorder	0.0013	0.00422	CbGpPWpGaD
Thalidomide—TNF—Signaling events mediated by HDAC Class I—EP300—attention deficit hyperactivity disorder	0.0013	0.00421	CbGpPWpGaD
Thalidomide—TNF—SIDS Susceptibility Pathways—HTR2A—attention deficit hyperactivity disorder	0.00129	0.00419	CbGpPWpGaD
Thalidomide—NFKB1—Developmental Biology—CACNA1C—attention deficit hyperactivity disorder	0.00126	0.00408	CbGpPWpGaD
Thalidomide—CYP2C19—Phase 1 - Functionalization of compounds—MAOA—attention deficit hyperactivity disorder	0.00124	0.00402	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—MB21D1—attention deficit hyperactivity disorder	0.00123	0.00399	CbGpPWpGaD
Thalidomide—TNF—Transcriptional regulation of white adipocyte differentiation—EP300—attention deficit hyperactivity disorder	0.0012	0.00391	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—STUB1—attention deficit hyperactivity disorder	0.00119	0.00387	CbGpPWpGaD
Thalidomide—PTGS2—Spinal Cord Injury—BDNF—attention deficit hyperactivity disorder	0.00118	0.00383	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—MB21D1—attention deficit hyperactivity disorder	0.00117	0.00379	CbGpPWpGaD
Thalidomide—PTGS1—Biological oxidations—COMT—attention deficit hyperactivity disorder	0.00115	0.00373	CbGpPWpGaD
Thalidomide—PTGS1—Biological oxidations—MAOA—attention deficit hyperactivity disorder	0.00114	0.0037	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—STUB1—attention deficit hyperactivity disorder	0.00113	0.00367	CbGpPWpGaD
Thalidomide—CYP2C9—Phase 1 - Functionalization of compounds—MAOA—attention deficit hyperactivity disorder	0.00113	0.00367	CbGpPWpGaD
Thalidomide—PTGS2—Aryl Hydrocarbon Receptor—EP300—attention deficit hyperactivity disorder	0.00112	0.00365	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—CACNB2—attention deficit hyperactivity disorder	0.00105	0.0034	CbGpPWpGaD
Thalidomide—FGFR2—Disease—STUB1—attention deficit hyperactivity disorder	0.00104	0.00339	CbGpPWpGaD
Thalidomide—CYP1A1—Aryl Hydrocarbon Receptor Pathway—EP300—attention deficit hyperactivity disorder	0.000997	0.00324	CbGpPWpGaD
Thalidomide—CYP1A1—Aryl Hydrocarbon Receptor—EP300—attention deficit hyperactivity disorder	0.000997	0.00324	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	0.000987	0.0032	CbGpPWpGaD
Thalidomide—CYP1A2—Phase 1 - Functionalization of compounds—MAOA—attention deficit hyperactivity disorder	0.000965	0.00313	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—CACNA1C—attention deficit hyperactivity disorder	0.000957	0.00311	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	0.000936	0.00304	CbGpPWpGaD
Thalidomide—NFKB1—Integrated Breast Cancer Pathway—EP300—attention deficit hyperactivity disorder	0.000921	0.00299	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—POLR3A—attention deficit hyperactivity disorder	0.000903	0.00293	CbGpPWpGaD
Thalidomide—NFKB1—SIDS Susceptibility Pathways—EP300—attention deficit hyperactivity disorder	0.000897	0.00291	CbGpPWpGaD
Thalidomide—CYP1A2—Phase II conjugation—COMT—attention deficit hyperactivity disorder	0.000882	0.00286	CbGpPWpGaD
Thalidomide—CYP2E1—Biological oxidations—COMT—attention deficit hyperactivity disorder	0.000858	0.00279	CbGpPWpGaD
Thalidomide—CYP3A5—Biological oxidations—COMT—attention deficit hyperactivity disorder	0.000857	0.00278	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—POLR3A—attention deficit hyperactivity disorder	0.000857	0.00278	CbGpPWpGaD
Thalidomide—CYP2E1—Biological oxidations—MAOA—attention deficit hyperactivity disorder	0.000852	0.00277	CbGpPWpGaD
Thalidomide—CYP3A5—Biological oxidations—MAOA—attention deficit hyperactivity disorder	0.000851	0.00276	CbGpPWpGaD
Thalidomide—CYP2E1—Metapathway biotransformation—COMT—attention deficit hyperactivity disorder	0.000847	0.00275	CbGpPWpGaD
Thalidomide—CYP3A5—Metapathway biotransformation—COMT—attention deficit hyperactivity disorder	0.000845	0.00274	CbGpPWpGaD
Thalidomide—CYP1A1—Biological oxidations—COMT—attention deficit hyperactivity disorder	0.000809	0.00263	CbGpPWpGaD
Thalidomide—CYP1A1—Biological oxidations—MAOA—attention deficit hyperactivity disorder	0.000804	0.00261	CbGpPWpGaD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—BDNF—attention deficit hyperactivity disorder	0.000803	0.00261	CbGpPWpGaD
Thalidomide—CYP1A1—Metapathway biotransformation—COMT—attention deficit hyperactivity disorder	0.000798	0.00259	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	0.00077	0.0025	CbGpPWpGaD
Thalidomide—NFKB1—Integrated Pancreatic Cancer Pathway—EP300—attention deficit hyperactivity disorder	0.000763	0.00248	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	0.000731	0.00237	CbGpPWpGaD
Thalidomide—PTGS2—C-MYB transcription factor network—EP300—attention deficit hyperactivity disorder	0.000694	0.00225	CbGpPWpGaD
Thalidomide—TNF—SIDS Susceptibility Pathways—EP300—attention deficit hyperactivity disorder	0.000684	0.00222	CbGpPWpGaD
Thalidomide—CYP2C19—Biological oxidations—COMT—attention deficit hyperactivity disorder	0.000662	0.00215	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	0.000662	0.00215	CbGpPWpGaD
Thalidomide—CYP2C19—Biological oxidations—MAOA—attention deficit hyperactivity disorder	0.000658	0.00214	CbGpPWpGaD
Thalidomide—CYP2C19—Metapathway biotransformation—COMT—attention deficit hyperactivity disorder	0.000653	0.00212	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	0.000648	0.00211	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	0.000636	0.00206	CbGpPWpGaD
Thalidomide—CYP1A2—Aryl Hydrocarbon Receptor—EP300—attention deficit hyperactivity disorder	0.000636	0.00206	CbGpPWpGaD
Thalidomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EP300—attention deficit hyperactivity disorder	0.000636	0.00206	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	0.000628	0.00204	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	0.000615	0.002	CbGpPWpGaD
Thalidomide—CYP2C9—Biological oxidations—COMT—attention deficit hyperactivity disorder	0.000604	0.00196	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	0.000603	0.00196	CbGpPWpGaD
Thalidomide—CYP2C9—Biological oxidations—MAOA—attention deficit hyperactivity disorder	0.0006	0.00195	CbGpPWpGaD
Thalidomide—CYP2C9—Metapathway biotransformation—COMT—attention deficit hyperactivity disorder	0.000596	0.00193	CbGpPWpGaD
Thalidomide—NFKB1—Cellular responses to stress—EP300—attention deficit hyperactivity disorder	0.000589	0.00191	CbGpPWpGaD
Thalidomide—TNF—Integrated Pancreatic Cancer Pathway—EP300—attention deficit hyperactivity disorder	0.000581	0.00189	CbGpPWpGaD
Thalidomide—PTGS2—Disease—STUB1—attention deficit hyperactivity disorder	0.000518	0.00168	CbGpPWpGaD
Thalidomide—CYP1A2—Biological oxidations—COMT—attention deficit hyperactivity disorder	0.000516	0.00168	CbGpPWpGaD
Thalidomide—CYP1A2—Biological oxidations—MAOA—attention deficit hyperactivity disorder	0.000512	0.00166	CbGpPWpGaD
Thalidomide—CYP1A2—Metapathway biotransformation—COMT—attention deficit hyperactivity disorder	0.000509	0.00165	CbGpPWpGaD
Thalidomide—CYP1A1—PPARA activates gene expression—EP300—attention deficit hyperactivity disorder	0.000496	0.00161	CbGpPWpGaD
Thalidomide—FGFR2—Disease—SNAP25—attention deficit hyperactivity disorder	0.000495	0.00161	CbGpPWpGaD
Thalidomide—CYP1A1—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—EP300—attention deficit hyperactivity disorder	0.000486	0.00158	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—ADRA2C—attention deficit hyperactivity disorder	0.00047	0.00153	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	0.000449	0.00146	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	0.000426	0.00138	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	0.000393	0.00128	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—ADRA2C—attention deficit hyperactivity disorder	0.000373	0.00121	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	0.000373	0.00121	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	0.000365	0.00119	CbGpPWpGaD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—EP300—attention deficit hyperactivity disorder	0.00036	0.00117	CbGpPWpGaD
Thalidomide—NFKB1—Developmental Biology—EP300—attention deficit hyperactivity disorder	0.000357	0.00116	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	0.000354	0.00115	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—ADRA2C—attention deficit hyperactivity disorder	0.000351	0.00114	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—ADRA2C—attention deficit hyperactivity disorder	0.00035	0.00114	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	0.000348	0.00113	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	0.000346	0.00113	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	0.000343	0.00111	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	0.000336	0.00109	CbGpPWpGaD
Thalidomide—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—EP300—attention deficit hyperactivity disorder	0.000335	0.00109	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—ADRA2C—attention deficit hyperactivity disorder	0.000331	0.00107	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	0.00033	0.00107	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	0.000326	0.00106	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—TPH2—attention deficit hyperactivity disorder	0.000324	0.00105	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—CACNB2—attention deficit hyperactivity disorder	0.000324	0.00105	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	0.00032	0.00104	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—DPYD—attention deficit hyperactivity disorder	0.000319	0.00104	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—EP300—attention deficit hyperactivity disorder	0.000315	0.00102	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	0.000303	0.000985	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—EP300—attention deficit hyperactivity disorder	0.000299	0.000971	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—CACNA1C—attention deficit hyperactivity disorder	0.000297	0.000963	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—EP300—attention deficit hyperactivity disorder	0.000272	0.000883	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—ADRA2C—attention deficit hyperactivity disorder	0.000271	0.000879	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—SNAP25—attention deficit hyperactivity disorder	0.000259	0.000842	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—TPH2—attention deficit hyperactivity disorder	0.000257	0.000836	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—CACNB2—attention deficit hyperactivity disorder	0.000257	0.000836	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—DPYD—attention deficit hyperactivity disorder	0.000253	0.000822	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—ADRA2C—attention deficit hyperactivity disorder	0.000247	0.000802	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—ADRA2A—attention deficit hyperactivity disorder	0.000247	0.000801	CbGpPWpGaD
Thalidomide—PTGS2—Disease—SNAP25—attention deficit hyperactivity disorder	0.000246	0.000798	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—TPH2—attention deficit hyperactivity disorder	0.000242	0.000787	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—CACNB2—attention deficit hyperactivity disorder	0.000242	0.000787	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—TPH2—attention deficit hyperactivity disorder	0.000242	0.000785	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—CACNB2—attention deficit hyperactivity disorder	0.000242	0.000785	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—DPYD—attention deficit hyperactivity disorder	0.000238	0.000774	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—DPYD—attention deficit hyperactivity disorder	0.000238	0.000772	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—CACNA1C—attention deficit hyperactivity disorder	0.000235	0.000764	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—TPH2—attention deficit hyperactivity disorder	0.000228	0.000742	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—CACNB2—attention deficit hyperactivity disorder	0.000228	0.000742	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—DPYD—attention deficit hyperactivity disorder	0.000225	0.00073	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	0.000224	0.000727	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—CACNA1C—attention deficit hyperactivity disorder	0.000222	0.00072	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—CACNA1C—attention deficit hyperactivity disorder	0.000221	0.000718	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	0.000213	0.00069	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—ADRA2C—attention deficit hyperactivity disorder	0.000211	0.000685	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—CACNA1C—attention deficit hyperactivity disorder	0.000209	0.000678	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—SNAP25—attention deficit hyperactivity disorder	0.000206	0.000668	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—COMT—attention deficit hyperactivity disorder	0.000196	0.000638	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—ADRA2A—attention deficit hyperactivity disorder	0.000196	0.000636	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—MAOA—attention deficit hyperactivity disorder	0.000195	0.000633	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—SNAP25—attention deficit hyperactivity disorder	0.000194	0.000629	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—SNAP25—attention deficit hyperactivity disorder	0.000193	0.000628	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism of lipids and lipoproteins—EP300—attention deficit hyperactivity disorder	0.000189	0.000614	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—TPH2—attention deficit hyperactivity disorder	0.000187	0.000607	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—CACNB2—attention deficit hyperactivity disorder	0.000187	0.000607	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—ADRA2A—attention deficit hyperactivity disorder	0.000184	0.000599	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—ADRA2A—attention deficit hyperactivity disorder	0.000184	0.000598	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—DPYD—attention deficit hyperactivity disorder	0.000184	0.000597	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—EP300—attention deficit hyperactivity disorder	0.000184	0.000596	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—SNAP25—attention deficit hyperactivity disorder	0.000183	0.000593	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—EP300—attention deficit hyperactivity disorder	0.000174	0.000566	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—ADRA2A—attention deficit hyperactivity disorder	0.000174	0.000565	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—CACNA1C—attention deficit hyperactivity disorder	0.000171	0.000555	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—TPH2—attention deficit hyperactivity disorder	0.00017	0.000553	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—CACNB2—attention deficit hyperactivity disorder	0.00017	0.000553	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—DPYD—attention deficit hyperactivity disorder	0.000168	0.000545	CbGpPWpGaD
Thalidomide—FGFR2—Disease—EP300—attention deficit hyperactivity disorder	0.000161	0.000522	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—COMT—attention deficit hyperactivity disorder	0.000156	0.000506	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—CACNA1C—attention deficit hyperactivity disorder	0.000156	0.000506	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—MAOA—attention deficit hyperactivity disorder	0.000155	0.000503	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism of lipids and lipoproteins—EP300—attention deficit hyperactivity disorder	0.00015	0.000488	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—SNAP25—attention deficit hyperactivity disorder	0.000149	0.000485	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—COMT—attention deficit hyperactivity disorder	0.000147	0.000477	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—COMT—attention deficit hyperactivity disorder	0.000146	0.000476	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—MAOA—attention deficit hyperactivity disorder	0.000146	0.000473	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—TPH2—attention deficit hyperactivity disorder	0.000146	0.000473	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—CACNB2—attention deficit hyperactivity disorder	0.000146	0.000473	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—MAOA—attention deficit hyperactivity disorder	0.000145	0.000472	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—DPYD—attention deficit hyperactivity disorder	0.000143	0.000465	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—ADRA2A—attention deficit hyperactivity disorder	0.000142	0.000462	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—COMT—attention deficit hyperactivity disorder	0.000138	0.000449	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—MAOA—attention deficit hyperactivity disorder	0.000137	0.000446	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—SNAP25—attention deficit hyperactivity disorder	0.000136	0.000442	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism of lipids and lipoproteins—EP300—attention deficit hyperactivity disorder	0.000133	0.000433	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—CACNA1C—attention deficit hyperactivity disorder	0.000133	0.000433	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—ADRA2A—attention deficit hyperactivity disorder	0.00013	0.000421	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—EP300—attention deficit hyperactivity disorder	0.000119	0.000385	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—SNAP25—attention deficit hyperactivity disorder	0.000116	0.000378	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—COMT—attention deficit hyperactivity disorder	0.000113	0.000368	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—EP300—attention deficit hyperactivity disorder	0.000113	0.000366	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—MAOA—attention deficit hyperactivity disorder	0.000112	0.000365	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—ADRA2A—attention deficit hyperactivity disorder	0.000111	0.00036	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—EP300—attention deficit hyperactivity disorder	0.000109	0.000354	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—COMT—attention deficit hyperactivity disorder	0.000103	0.000335	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—MAOA—attention deficit hyperactivity disorder	0.000103	0.000333	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—EP300—attention deficit hyperactivity disorder	9.94e-05	0.000323	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—COMT—attention deficit hyperactivity disorder	8.82e-05	0.000287	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—MAOA—attention deficit hyperactivity disorder	8.76e-05	0.000285	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—EP300—attention deficit hyperactivity disorder	8.5e-05	0.000276	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—EP300—attention deficit hyperactivity disorder	8.42e-05	0.000274	CbGpPWpGaD
Thalidomide—PTGS2—Disease—EP300—attention deficit hyperactivity disorder	7.98e-05	0.000259	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—EP300—attention deficit hyperactivity disorder	6.69e-05	0.000217	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—EP300—attention deficit hyperactivity disorder	6.29e-05	0.000204	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—EP300—attention deficit hyperactivity disorder	6.28e-05	0.000204	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—EP300—attention deficit hyperactivity disorder	5.93e-05	0.000193	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—EP300—attention deficit hyperactivity disorder	4.86e-05	0.000158	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—EP300—attention deficit hyperactivity disorder	4.43e-05	0.000144	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—EP300—attention deficit hyperactivity disorder	3.78e-05	0.000123	CbGpPWpGaD
